Fate Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Fate Therapeutics

08/08/2025 13:56

Fate Therapeutics Inc FATE.OQ FATE.O is expected to  show a fall in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

The San Diego California-based  company is expected to report a 85.1% decrease in revenue to $1.011 million from $6.77 million a year ago, according to the mean estimate from 10 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Fate Therapeutics Inc is for a loss of 34 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Fate Therapeutics Inc is $5.00, about 80.4% above its last closing price of $0.98

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.38
-0.38
-0.32
Beat
16.4
Dec. 31 2025
-0.43
-0.43
-0.44
Missed
-1.7
Sep. 30 2024
-0.41
-0.43
-0.40
Beat
7.5​
Jun. 30 2024
-0.47
-0.48
-0.33
Beat
30.6
​​Mar. 31 2024
-0.48
-0.49
-0.47
Beat
3.8
Dec. 31 2023
-0.53
-0.52
-0.45
Beat
13.9​
Sep. 30 2023
-0.56
-0.57
-0.46
Beat
19.3
Jun. 30 2023
-0.58
-0.59
-0.54
Beat
8.2

This summary was machine generated August 8 at 12:56 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)